Lyell Immunopharma (LYEL) Initiated with Buy Rating and $44 Target
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowStifel has initiated coverage of Lyell Immunopharma (LYEL) with a buy rating and a price target of $44. This rating suggests confidence in the stock's potential performance. Initiating coverage can impact market perception and investor interest, potentially leading to increased trading volume. For investors, this rating indicates possible appreciation in stock value for Lyell Immunopharma.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
